260 related articles for article (PubMed ID: 28984303)
1. Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma.
Zilberg C; Lee MW; Yu B; Ashford B; Kraitsek S; Ranson M; Shannon K; Cowley M; Iyer NG; Palme CE; Ch'ng S; Low TH; O'Toole S; Clark JR; Gupta R
Mod Pathol; 2018 Feb; 31(2):275-287. PubMed ID: 28984303
[TBL] [Abstract][Full Text] [Related]
2. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
3. Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies?
Zilberg C; Lee MW; Kraitsek S; Ashford B; Ranson M; Shannon K; Iyer NG; Ch'ng S; Low TH; Palme C; Clark J; Gupta R; Yu B
J Clin Pathol; 2020 Jan; 73(1):17-22. PubMed ID: 31300530
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma.
Ohmoto A; Sato Y; Asaka R; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takeuchi K; Mori S; Takahashi S
Mod Pathol; 2021 Nov; 34(11):1979-1989. PubMed ID: 34247193
[TBL] [Abstract][Full Text] [Related]
5. Comparing Genomic Landscapes of Oral and Cutaneous Squamous Cell Carcinoma of the Head and Neck: Quest for Novel Diagnostic Markers.
Gupta R; Strbenac D; Satgunaseelan L; Cheung VK; Narayanappa H; Ashford B; Mitchell J; Thind A; Palme CE; Ch'ng S; Low TH; Wykes J; Willet CE; Chew T; Yang J; Ranson M; Clark JR
Mod Pathol; 2023 Aug; 36(8):100190. PubMed ID: 37080394
[TBL] [Abstract][Full Text] [Related]
6. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
7. Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation.
Tinhofer I; Stenzinger A; Eder T; Konschak R; Niehr F; Endris V; Distel L; Hautmann MG; Mandic R; Stromberger C; Weichert W; Budach V
Ann Oncol; 2016 Dec; 27(12):2262-2268. PubMed ID: 27681865
[TBL] [Abstract][Full Text] [Related]
8. Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma.
Ock CY; Son B; Keam B; Lee SY; Moon J; Kwak H; Kim S; Kim TM; Jeon YK; Kwon SK; Hah JH; Lee SH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
J Cancer Res Clin Oncol; 2016 Apr; 142(4):873-83. PubMed ID: 26677030
[TBL] [Abstract][Full Text] [Related]
9. Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation.
Harms PW; Collie AM; Hovelson DH; Cani AK; Verhaegen ME; Patel RM; Fullen DR; Omata K; Dlugosz AA; Tomlins SA; Billings SD
Mod Pathol; 2016 Mar; 29(3):240-8. PubMed ID: 26743471
[TBL] [Abstract][Full Text] [Related]
10. Targeted next-generation sequencing of matched localized and metastatic primary high-risk SCCs identifies driver and co-occurring mutations and novel therapeutic targets.
Lobl MB; Clarey D; Higgins S; Sutton A; Hansen L; Wysong A
J Dermatol Sci; 2020 Jul; 99(1):30-43. PubMed ID: 32595073
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
12. Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature.
Chen SJ; Liu H; Liao CT; Huang PJ; Huang Y; Hsu A; Tang P; Chang YS; Chen HC; Yen TC
Oncotarget; 2015 Jul; 6(20):18066-80. PubMed ID: 25980437
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
[TBL] [Abstract][Full Text] [Related]
14. Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma.
Lim SM; Cho SH; Hwang IG; Choi JW; Chang H; Ahn MJ; Park KU; Kim JW; Ko YH; Ahn HK; Cho BC; Nam BH; Chun SH; Hong JH; Kwon JH; Choi JG; Kang EJ; Yun T; Lee KW; Kim JH; Kim JS; Lee HW; Kim MK; Jung D; Kim JE; Keam B; Yun HJ; Kim S; Kim HR
Cancer Res Treat; 2019 Jan; 51(1):300-312. PubMed ID: 29747488
[TBL] [Abstract][Full Text] [Related]
15. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
16. All-Exon TP53 Sequencing and Protein Phenotype Analysis Accurately Predict Clinical Outcome after Surgical Treatment of Head and Neck Squamous Cell Carcinoma.
Kobayashi K; Yoshimoto S; Matsumoto F; Ando M; Murakami N; Omura G; Fukasawa M; Matsumoto Y; Matsumura S; Akamatsu M; Hiraoka N; Eigitsu R; Mori T
Ann Surg Oncol; 2019 Jul; 26(7):2294-2303. PubMed ID: 30900104
[TBL] [Abstract][Full Text] [Related]
17. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of oral squamous cell carcinoma using targeted next-generation sequencing.
Er TK; Wang YY; Chen CC; Herreros-Villanueva M; Liu TC; Yuan SS
Oral Dis; 2015 Oct; 21(7):872-8. PubMed ID: 26173098
[TBL] [Abstract][Full Text] [Related]
19. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.
Agrawal N; Frederick MJ; Pickering CR; Bettegowda C; Chang K; Li RJ; Fakhry C; Xie TX; Zhang J; Wang J; Zhang N; El-Naggar AK; Jasser SA; Weinstein JN; TreviƱo L; Drummond JA; Muzny DM; Wu Y; Wood LD; Hruban RH; Westra WH; Koch WM; Califano JA; Gibbs RA; Sidransky D; Vogelstein B; Velculescu VE; Papadopoulos N; Wheeler DA; Kinzler KW; Myers JN
Science; 2011 Aug; 333(6046):1154-7. PubMed ID: 21798897
[TBL] [Abstract][Full Text] [Related]
20. Squamous cell carcinoma initially occurring on the tongue dorsum: a case series report with molecular analysis.
Ono S; Hirose K; Sukegawa S; Obata K; Masui M; Hasegawa K; Fujimura A; Shimada K; Nakamura S; Teramoto A; Hori Y; Morii E; Motooka D; Igawa T; Tanaka T; Nagatsuka H; Toyosawa S; Yamamoto H
Diagn Pathol; 2024 Apr; 19(1):63. PubMed ID: 38650013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]